Clinical Trials
9 trialsNCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03139370 2023-08-25
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03608618 2021-09-05
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
MaxCyte, Inc.
Phase 1 Terminated
NCT03992326 2021-03-18
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Centre Hospitalier Universitaire Vaudois
Phase 1 Terminated
NCT01143545 2020-03-03
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00003194 2019-04-05
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Seattle Children's Hospital
Phase 1 Terminated
NCT02070406 2019-02-28
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Jonsson Comprehensive Cancer Center
Phase 1 Terminated